News | Intra-Vascular Ultrasound (IVUS) | February 29, 2016

Study Finds Intravascular Ultrasound Beneficial in Diagnosing Vein Obstructions

IVUS finds 88 percent more lesions than gold-standard multiplanar X-ray venography

Philips, Volcano, IVUS, vein obstruction diagnosis, multiplanar X-ray venography, VIDIO study

February 29, 2016 — Philips announced that new clinical trial data demonstrates the benefits of its intravascular ultrasound (IVUS) technology in the diagnosis of iliofemoral venous obstruction i.e. narrowed or blocked leg veins. The study, which compared IVUS to conventional contrast-enhanced X-ray imaging of the veins (also known as multiplanar X-ray venography), was presented by Paul J. Gagne, M.D., chief of vascular surgery at Norwalk Hospital in Norwalk, Conn.

In image-guided treatments of the blood vessels, there is an increasing trend to use IVUS catheters that are capable of producing ultrasound images of the interior of blood vessels. There is a growing body of clinical evidence that the use of this technology in conjunction with interventional X-ray helps improve procedural outcomes.

In the 100-patient prospective multicenter Venogram Versus Intravascular Ultrasound for Diagnosing Iliofemoral Vein Obstruction (VIDIO) study, 29 percent of patients were assessed to be free of lesions based on their X-ray venogram results, but had lesions detected by Philips Volcano’s phased-array IVUS technology. The results of the study, in which IVUS in total detected 88 percent more lesions than multiplanar X-ray venography (as assessed by investigators at the point-of-care), were announced at the American Venous Forum 28th annual meeting.

Iliac/common femoral vein obstruction (ICFVO) is a significant cause of chronic venous insufficiency (CVI) — a condition that is estimated to affect between 10-35 percent of adults in the United States, resulting in approximately 4.6 million lost workdays. Iliofemoral vein obstruction, which can eventually lead to swelling, chronic pain and ulceration, can be treated via angioplasty and stenting with profound benefits to the patient’s quality of life. However, many patients exhibiting symptoms may not be diagnosed with venography. There is, therefore, a real need for better ways to diagnose the condition.

“These results of the VIDIO study clearly show that IVUS is better at detecting lesions than multiplanar X-ray venography, the prior imaging gold standard,” said Gagne, global principal investigator of the study. “IVUS is now my preferred imaging modality of choice for identifying this treatable condition, and the VIDIO study shows how well these patients can do with the appropriate treatment.”

The study was designed to prospectively compare the diagnostic performance of conventional multiplanar venography versus IVUS for diagnosing and treating ICFVO; and to characterize patient response to iliofemoral vein intervention in terms of clinical improvement and quality of life over six months of follow-up.

Between July 2014 and July 2015, the study enrolled 100 patients with advanced venous insufficiency (CEAP* score 4, 5 and 6) at 11 U.S. and three European centers. Each patient had a multiplanar venogram performed, with an initial lesion characterization and treatment strategy recorded by the interventionalist based on the venogram. An assessment with Philips Volcano phased-array IVUS was then performed, with a second lesion characterization and treatment strategy recorded by the interventionalist. Stenting treatment was subsequently performed at the discretion of the interventionalist. All patients were followed for six months after the index procedure.

Across the full 100 patients enrolled, according to investigator readings at the time of the index procedure, IVUS detected 88 percent more lesions than multiplanar venography (124 vs 66) (P < .0001). In addition, 29 percent of patients were ruled negative by venograms, while showing positive findings from IVUS (19 vs 48).

For more information: www.volcanocorp.com

Related Content

News | Cath Lab

May 31, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, announced that the company has received ...

Home May 31, 2022
Home
News | Cath Lab

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has ...

Home May 26, 2022
Home
News | Cath Lab
April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...
Home April 25, 2022
Home
News | Cath Lab
April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...
Home April 18, 2022
Home
News | Cath Lab
February 16, 2022 – Fremont Bank Foundation recently donated $750,000 to its community partner, St. Rose Hospital ...
Home February 16, 2022
Home
News | Cath Lab
February 14, 2022 — A collaborative effort between The Valley Heart and Vascular Institute’s cardiology team ...
Home February 14, 2022
Home
Sponsored Content | Videos | Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

Home January 13, 2022
Home
News | Cath Lab

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has authorized marketing of the first laser-based device ...

Home January 04, 2022
Home
News | Cath Lab

December 14, 2021 — RSIP Vision, a medical imaging company applying advanced artificial intelligence (AI) and computer ...

Home December 14, 2021
Home
Feature | Cath Lab

November 15, 2021 — RealView Imaging Ltd. recently received FDA 510(k) clearance for its Holoscope-i holographic system ...

Home November 15, 2021
Home
Subscribe Now